Other brain & spinal cord tumors

This guide covers several uncommon central nervous system tumors, rather than one disease. A pineal-region mass, for example, may be a germinoma, a pineal parenchymal tumor or a non-tumor cyst. Their treatments are not interchangeable. Tumors spreading from another organ to the brain also follow a different pathway from primary brain tumors.

If an old report says only “embryonal tumor,” “PNET” or “brain tumor,” specialist neuropathology review may be needed. The useful endpoint is an integrated diagnosis that combines the tissue appearance with appropriate molecular tests, not simply a longer list of gene changes.

For these more common diagnoses, use the dedicated guides:

Contrast-enhanced MRI defines the lesion and its relationship to critical structures. Spine imaging, cerebrospinal fluid testing, eye examination, tumor markers or endocrine assessment are added according to the suspected diagnosis. Lumbar puncture is not a routine first step when pressure or obstruction makes it unsafe.

Agree the purpose of surgery before the procedure: obtain diagnostic tissue, relieve obstructed fluid flow, remove the tumor, or combine these goals. For a lesion near the pituitary or hypothalamus, document vision, hormone function and fluid balance before treatment so that changes can be recognized afterwards.

Primary CNS lymphoma can involve the brain, eyes, cerebrospinal fluid or spinal cord without lymphoma elsewhere at diagnosis. Work-up checks for disease outside the CNS as well as within it. Diagnosis usually relies on a biopsy; routine extensive brain resection is not the standard approach.

Corticosteroids can obscure lymphoma tissue findings. When clinically feasible, the team plans tissue sampling before steroids; urgent neurological deterioration takes priority. Tell the team about any steroid use and do not stop prescribed steroids on your own.

High-dose methotrexate-based combinations are central to treatment. Selection depends on kidney function, fitness, other illnesses and the ability to monitor drug clearance and toxicity. A regimen such as MATRix is intensive and is not appropriate for every patient; ordinary lymphoma regimens cannot simply be substituted for CNS-directed treatment.

After a response, consolidation aims to make disease control last. The randomized MATRix/IELSG43 trial published in 2026 found better progression-free survival with high-dose chemotherapy and autologous stem-cell transplantation than with R-DeVIC consolidation in selected patients who responded to induction. Transplant treatment caused more adverse events, including serious and fatal complications.

This result supports a specific pathway for patients fit for intensive treatment; it does not make transplantation mandatory for every age or health condition. Other strategies, including selected radiotherapy approaches, require discussion of relapse risk and delayed cognitive toxicity. At relapse, previous response, treatment interval and trial eligibility guide the next plan.

Germinoma, nongerminomatous germ cell tumors and teratoma have different treatment paths. Serum and, when safe, cerebrospinal fluid AFP and beta-hCG help classify the disease; the marker thresholds and need for a biopsy depend on the protocol and clinical findings. Brain and spine staging assess spread. A pineal and suprasellar double lesion is not automatically equivalent to widespread disease.

Localized germinoma is highly sensitive to radiotherapy, often combined with chemotherapy to adapt radiation exposure. The final SIOP-CNS-GCT II report in 2026 supports omitting the tumor-bed boost in appropriately staged localized cases reaching complete remission after the study chemotherapy, while retaining whole-ventricular radiotherapy. This is not evidence for omitting all radiotherapy or using focal treatment alone.

Nongerminomatous tumors generally need combined chemotherapy and radiotherapy, with surgery considered for selected residual masses. A growing mass with normalized markers may contain mature teratoma rather than simply chemotherapy-resistant cancer. Excessive thirst and urination can reflect diabetes insipidus; fluid and hormone management matter during treatment.

Craniopharyngioma is usually histologically benign, but its proximity to the optic pathways, pituitary and hypothalamus can make it a serious lifelong condition. Adamantinomatous and papillary craniopharyngioma are distinct tumor types. Treatment balances control against damage to vision, hormone production, appetite regulation, sleep and memory.

Depending on the anatomy, options include a carefully limited operation followed by radiotherapy, more complete resection when safe, or drainage and treatment of a symptomatic cyst. Complete removal is not automatically the best choice if it sacrifices hypothalamic function. Endocrine follow-up and an agreed hormone-replacement plan remain important even when imaging shows good control.

Papillary craniopharyngioma commonly has a BRAF V600E alteration. A small single-arm phase 2 study of vemurafenib plus cobimetinib reported substantial shrinkage in 15 of 16 evaluable patients. This can support specialist discussion of treatment before a difficult local procedure or in selected recurrent disease.

The study also reported substantial toxicity. Tumor shrinkage is not the same as a proven cure or proof that surgery and radiotherapy can always be avoided. The result does not apply to all craniopharyngiomas, particularly adamantinomatous tumors without this alteration. The team must confirm the molecular result, treatment purpose, monitoring and local prescribing access.

A pineal-region lesion can obstruct cerebrospinal fluid flow and cause hydrocephalus. Relieving that obstruction and obtaining a diagnosis may come before definitive tumor treatment. Pineocytoma is often managed with surgery alone after complete removal; pineoblastoma is an aggressive embryonal tumor requiring an age- and spread-adapted multimodal plan.

Pineal parenchymal tumors of intermediate differentiation sit on another pathway. Grade, residual disease and dissemination inform discussion of radiotherapy, but prospective evidence remains limited. Molecular review can resolve difficult diagnoses. Genetic counseling may be relevant in pineoblastoma. An incidental pineal cyst should not be relabeled as cancer merely because it appears on an MRI.

Atypical teratoid/rhabdoid tumor (AT/RT) is an aggressive tumor often affecting very young children. SMARCB1 or, less often, SMARCA4 alterations help establish the diagnosis; methylation profiling may clarify the subtype. Treatment usually involves a pediatric neuro-oncology team coordinating surgery, intensive medicines and carefully planned radiation. Genetic evaluation matters because some changes are inherited.

For a spinal lesion, clarify whether it is inside the cord, outside the cord but within its covering, or arising in the vertebrae. This affects biopsy, surgical risk and whether the problem is a primary tumor or metastasis. New progressive weakness, inability to walk or loss of bladder control needs urgent assessment rather than waiting for a planned second opinion.

Follow-up should track both tumor control and everyday function. Depending on the tumor and treatment, this includes vision, hearing, cognition, school or work, mobility, seizures and hormone function. Stable MRI findings do not exclude treatment-related problems. Children may need support that changes as they grow.

For a specialist review, collect original MRI files, pathology slides or blocks, molecular reports, surgery notes, radiation plans, medication history and the recent neurological or endocrine assessment. Ask what remains uncertain, which additional test would change the plan, and how the proposal protects function. Access to a trial or a molecular drug must be checked for the exact tumor, age and treatment history.